Condition: Advanced Solid Tumor · Sponsor: Callio Therapeutics
The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.
This description comes directly from the study's public registry record.
CMO · 206-602-3134 · clinical@calliotx.com
Always discuss trial participation with your own doctor first.
| DFCI | Boston, Massachusetts, United States | Not Yet Recruiting |
| Sarah Cannon Research Institute 335 24th Avenue North, Suite 400 | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| START Mountain | West Valley City, Utah, United States | Recruiting |
| Scientia Clinical Research | Randwick, New South Wales, Australia | Recruiting |
| Integrated Clinical Oncology Network Pty Ltd | South Brisbane, Queensland, Australia | Recruiting |
| Peter Maccallum Cancer Centre | Box Hill, Victoria, Australia | Recruiting |
| AlfredHealth | Heidelberg, Victoria, Australia | Recruiting |
| Royal Melbourne Hospital | Melbourne, Victoria, Australia | Recruiting |
| Linear Clinical Research Ltd | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07300943